Trial Profile
A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix Administered Intramuscularly in Elderly Aged 60 Years Old and Above.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 1247446A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 14 Nov 2011 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
- 27 Oct 2008 Trial end date changed from 1 Dec 2006 to 1 Jul 2006 as reported by ClinicalTrials.gov.
- 14 Oct 2008 New trial record.